New Evidence Supports Use of Weight-Loss Medication for Schizophrenia Patients

Recent research conducted by the University of Queensland has demonstrated that certain diabetic weight-loss medications are both effective and safe for individuals with schizophrenia, without exacerbating their psychiatric symptoms. In a 36-week clinical trial, the medication semaglutide—commonly found in drugs like Ozempic and Wegovy—was shown to significantly aid weight loss among patients, a crucial development given the high risk of obesity-related complications in this population.

Patients with schizophrenia often experience weight gain due to antipsychotic medications, such as clozapine, which many find difficult to tolerate long-term. This weight gain can lead to a substantial reduction in life expectancy, with the gap to the general population's lifespan extending to approximately 16 years. The trial revealed that participants taking semaglutide lost nearly 14% of their body weight, compared to those on a placebo, suggesting strong therapeutic potential.

Importantly, the study found that semaglutide did not interfere with mental health, psychotic symptoms, or the levels of antipsychotic drugs. It also improved the ratio of lean to fat mass, indicating more effective fat loss. These findings are particularly notable because they were obtained without pharmaceutical company involvement, adding to their credibility.

Currently, in Australia, semaglutide is not included in the Pharmaceutical Benefits Scheme (PBS) for weight management, underscoring the need for wider access due to the urgent health disparities faced by people with schizophrenia. Experts advocate for policy changes to improve affordability and availability, enabling this vulnerable group to benefit from such effective treatment options.

This pioneering research, published in The Lancet Psychiatry, offers a promising avenue for improving physical health outcomes in individuals with schizophrenia, supporting both weight management and overall well-being.